Entera Bio
ENTXEntera Bio is a clinical-stage biotechnology company specializing in the development of oral peptide and protein replacement therapies.
$193.22M+110%
Table of contents
Earnings
Next report
Aug 14, 2026 (In 2 weeks)EPS estimate-$0.08
Competitors
By market cap
Profile
Entera Bio is a clinical-stage biotechnology company specializing in the development of oral peptide and protein replacement therapies. The company utilizes its proprietary N-Tab platform to transform injectable treatments into oral formulations, targeting significant unmet medical needs in bone health and endocrine disorders.
Competitive position
An early-stage innovator focused on the high-barrier challenge of oral delivery for large molecule proteins and peptides.
GeographiesGlobal, Israel, United States
Customer segmentsPatients, Strategic partners
Business modelR&D intensive, Licensing, Clinical-stage development
SuppliersRaw material suppliers, Contract research organizations, Intellectual property licensors
CustomersLarge pharmaceutical companies, Specialty pharmacies, Hospitals
CountryIsrael
Listed2018
Employees19.0
CEOMiranda J. Toledano
SectorHealthcare
IndustryBiotechnology
Websiteenterabio.com
FilingsSEC EDGAR
Questions, answered.
- What is Entera Bio's market cap?
- Entera Bio (ENTX) has a market capitalization of $193.2M and trades on NASDAQ.
- Who are Entera Bio's competitors?
- Entera Bio's key competitors include Eli Lilly and Company, Amgen Inc., Septerna, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Entera Bio headquartered?
- Entera Bio is headquartered in Israel and employs approximately 19 people. It has been publicly traded since 2018.